Author details

Full Name

Elisa de Stanchina

Affiliation

ORCID

Career Start Year

1997

Papers

234

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36917886	Fully human monoclonal antibody targeting activated ADAM10 on colorectal cancer cells.	Biomed Pharmacother	2023
36240971	Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.	J Thorac Oncol	2023
36355783	Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer.	Cancer Discov	2023
36264143	A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.	Cancer Discov	2023
36259947	Identifying the Transcriptional Drivers of Metastasis Embedded within Localized Melanoma.	Cancer Discov	2023
37743366	Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.	Nat Cancer	2023
37814012	Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.	Nat Cancer	2023
37802054	Cooperative CAR targeting to selectively eliminate AML and minimize escape.		2023
37696659	Patient-Derived-Xenografts in Mice: A Preclinical Platform for Cancer Research.		2023
37616543	Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.		2023
37691854	A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer.	Cancer Res Commun	2023
37609261	Interferon response and epigenetic modulation by <i>SMARCA4</i> mutations drive ovarian tumor immunogenicity.	bioRxiv	2023
36913051	Antitumor activity of the PI3K Î´-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2â¿¿+â¿¿breast cancer.		2023
37142692	EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance.		2023
36574773	The ectonucleotidase CD39 identifies tumor-reactive CD8<sup>+</sup> TÂ cells predictive of immune checkpoint blockade efficacy in human lung cancer.	Immunity	2023
37258666	Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.		2023
37127830	Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies.	Nat Immunol	2023
37382635	De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways.	Clin Cancer Res	2023
37001526	Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.	Cancer Cell	2023
36868194	hPSC-derived sacral neural crest enables rescue in a severe model of Hirschsprung's disease.	Cell Stem Cell	2023
36934096	Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma.		2023
36798379	Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy.	bioRxiv	2023
37182602	Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.	J Thorac Oncol	2023
36611031	Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers.	Nat Commun	2023
37045815	Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models.		2023
36991128	STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma.	Nature	2023
37531417	Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.	Sci Transl Med	2023
35082152	Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2022
35394541	KRAS Mutants Upregulate Integrin Î²4 to Promote Invasion and Metastasis in Colorectal Cancer.	Mol Cancer Res	2022
35584676	WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.	Cell Rep	2022
36167829	TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.	Nature Communications	2022
35442775	A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets.	Proc Natl Acad Sci U S A	2022
35952360	Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State.	Cancer Res	2022
35952322	Prospective Clinical Genomic Profiling of Ewing Sarcoma: <i>ERF</i> and <i>FGFR1</i> Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance.	JCO Precis Oncol	2022
35440124	Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts.	Nat Commun	2022
35691495	Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.	J Thorac Oncol	2022
35626002	Frequent 4EBP1 Amplification Induces Synthetic Dependence on FGFR Signaling in Cancer.	Cancers (Basel)	2022
35999225	ERÎ±-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance.	NPJ Breast Cancer	2022
35617398	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.	Science	2022
35613620	ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1.	Mol Cell	2022
35726024	Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia.	Nat Metab	2022
36380343	Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library.	Genome Med	2022
36476495	Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.		2022
35300079	A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors.	ACS Medicinal Chemistry Letters	2022
35046813	Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury.	Front Pharmacol	2022
35257504	Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor.	Pharmacol Res Perspect	2022
34907079	ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.	Clinical Cancer Research	2022
35149545	MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.	Mol Cancer Res	2022
34841430	Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling.	Dis Model Mech	2022
35135829	Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.	Cancer Discov	2022